Brook Baker, a law pro­fessor at North­eastern Uni­ver­sity, “said he doubts the phar­ma­ceu­tical industry will pull back much on its invest­ments in India based on the deci­sion,” Bloomberg News writes. “The country will still grant 20 year patents on new, inno­v­a­tive drugs and a growing middle class with chronic dis­eases will pro­vide many busi­ness oppor­tu­ni­ties, he said.”

Read the article at NPR →